BRPI0706992C8 - composto de fórmula (i) e formulação farmacêutica - Google Patents
composto de fórmula (i) e formulação farmacêuticaInfo
- Publication number
- BRPI0706992C8 BRPI0706992C8 BRPI0706992A BRPI0706992A BRPI0706992C8 BR PI0706992 C8 BRPI0706992 C8 BR PI0706992C8 BR PI0706992 A BRPI0706992 A BR PI0706992A BR PI0706992 A BRPI0706992 A BR PI0706992A BR PI0706992 C8 BRPI0706992 C8 BR PI0706992C8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical formulation
- formula
- pyrone
- stereoisomer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
Abstract
composto, formulação farmacêutica, e uso de um composto, sal ou estereoisômero a presente invenção refere-se a novos derivados de pirona-indol, às formulações farmacêuticas que contêm os mesmos e à utilização dos compostos na manufatura de medicamentos para o tratamento ou a prevenção de várias doenças.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77332206P | 2006-02-15 | 2006-02-15 | |
US60/773,322 | 2006-02-15 | ||
PCT/IB2007/000330 WO2007093880A2 (en) | 2006-02-15 | 2007-02-13 | Novel pyrone-indole derivatives and process for their preparation |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0706992A2 BRPI0706992A2 (pt) | 2011-04-12 |
BRPI0706992B1 BRPI0706992B1 (pt) | 2021-05-04 |
BRPI0706992C1 BRPI0706992C1 (pt) | 2021-05-18 |
BRPI0706992C8 true BRPI0706992C8 (pt) | 2021-05-25 |
Family
ID=38283075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0706992A BRPI0706992C8 (pt) | 2006-02-15 | 2007-02-13 | composto de fórmula (i) e formulação farmacêutica |
Country Status (22)
Country | Link |
---|---|
US (3) | US7635710B2 (pt) |
EP (1) | EP1991541B1 (pt) |
JP (1) | JP5248332B2 (pt) |
KR (1) | KR101207736B1 (pt) |
CN (1) | CN101374833B (pt) |
AU (1) | AU2007216226B2 (pt) |
BR (1) | BRPI0706992C8 (pt) |
CA (1) | CA2642465C (pt) |
DK (1) | DK1991541T3 (pt) |
EA (1) | EA015605B1 (pt) |
ES (1) | ES2428873T3 (pt) |
HK (1) | HK1126760A1 (pt) |
IL (1) | IL193236A (pt) |
NO (1) | NO339826B1 (pt) |
NZ (1) | NZ569797A (pt) |
PL (1) | PL1991541T3 (pt) |
PT (1) | PT1991541E (pt) |
SI (1) | SI1991541T1 (pt) |
TW (1) | TWI501960B (pt) |
UA (1) | UA104988C2 (pt) |
WO (1) | WO2007093880A2 (pt) |
ZA (1) | ZA200806799B (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
CN103319467B (zh) * | 2013-06-15 | 2015-10-14 | 湖南科技大学 | 一种4-[5-羟基-4-吡喃酮-2-基亚甲氨基]-3-巯基-1,2,4-三唑化合物及用途 |
PL3095781T3 (pl) * | 2014-01-14 | 2019-01-31 | Astellas Pharma Inc. | Związek indolowy |
RU2561045C1 (ru) * | 2014-07-15 | 2015-08-20 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный университет" (ФГБОУ ВПО "КубГУ") | Нейропротекторное фармакологическое средство |
WO2016039750A1 (en) | 2014-09-11 | 2016-03-17 | Halliburton Energy Services, Inc. | Cyanamide-based carbon dioxide and/or hydrogen sulfide scavengers and methods of use in subterranean operations |
CA2977135C (en) | 2015-02-25 | 2023-08-22 | The Regents Of The University Of California | 5ht agonists for treating disorders |
JP6910424B2 (ja) * | 2016-08-23 | 2021-07-28 | ニューリム・ファーマシューティカルズ・リミテッドNeurim Pharmaceuticals Ltd. | 掻痒症および/または痒みの治療方法 |
WO2019028234A1 (en) * | 2017-08-04 | 2019-02-07 | Ovid Therapeutics Inc. | USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS |
CN111683976B (zh) | 2018-02-05 | 2022-11-18 | 生物辐射实验室股份有限公司 | 具有阴离子交换-疏水混合模式配体的色谱树脂 |
MX2021003302A (es) | 2018-09-20 | 2021-05-13 | Ovid Therapeutics Inc | Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez. |
CA3123876A1 (en) | 2018-12-17 | 2020-06-25 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |
EP4149458A4 (en) * | 2020-05-11 | 2024-06-05 | B G Negev Technologies And Applications Ltd At Ben Gurion Univ | COMPOSITIONS OF TRYPTOPHOL DERIVATIVES AND 4-ETHYL-PHENOL DERIVATIVES, AND METHODS OF USE THEREOF |
WO2022238905A1 (en) | 2021-05-11 | 2022-11-17 | Neurim Pharmaceuticals (1991) Ltd. | Method for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locus |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA222247A (en) | 1922-08-15 | Hubert Rogers Reginald | Pocket container for confections | |
IT1196849B (it) | 1986-12-16 | 1988-11-25 | Rotta Research Lab | Nuovi derivati degli acidi 5 pentilammino 5 oxo pentaoico e 4 pentilammino 4 oxo butanoico ad attivita antagonista della colecistochinina e procedimento per la loro preparazione |
WO1992007829A1 (en) | 1990-11-02 | 1992-05-14 | The Upjohn Company | Indole-3-methanamines useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents |
US5840751A (en) * | 1993-11-19 | 1998-11-24 | Warner-Lambert Company | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents |
CN1215835C (zh) * | 1996-03-27 | 2005-08-24 | 东丽株式会社 | 酮衍生物及其在医学上的应用 |
IL130169A (en) | 1999-05-27 | 2006-08-20 | Neurim Pharma 1991 | Indole derivatives, and pharmaceutical preparations, skin protection preparations, and cosmetics containing them |
CA2406271A1 (en) * | 2000-04-18 | 2001-10-25 | Cytovia, Inc. | Substituted 1,4-thiazepine and analogs and their use as activators of caspases |
PE20060303A1 (es) | 2004-06-23 | 2006-05-19 | Wyeth Corp | Metabolitos de indolilalquilamina como ligandos de 5-hidroxitriptamina-6 |
US7834050B2 (en) * | 2006-03-29 | 2010-11-16 | Duke University | Small molecule insulin mimetics absent quinones |
-
2007
- 2007-02-12 US US11/705,030 patent/US7635710B2/en active Active
- 2007-02-13 KR KR1020087022304A patent/KR101207736B1/ko active IP Right Grant
- 2007-02-13 EP EP07733884.6A patent/EP1991541B1/en active Active
- 2007-02-13 ES ES07733884T patent/ES2428873T3/es active Active
- 2007-02-13 WO PCT/IB2007/000330 patent/WO2007093880A2/en active Application Filing
- 2007-02-13 CA CA2642465A patent/CA2642465C/en active Active
- 2007-02-13 CN CN2007800039654A patent/CN101374833B/zh active Active
- 2007-02-13 UA UAA200808838A patent/UA104988C2/uk unknown
- 2007-02-13 SI SI200731333T patent/SI1991541T1/sl unknown
- 2007-02-13 JP JP2008554868A patent/JP5248332B2/ja active Active
- 2007-02-13 PL PL07733884T patent/PL1991541T3/pl unknown
- 2007-02-13 DK DK07733884.6T patent/DK1991541T3/da active
- 2007-02-13 AU AU2007216226A patent/AU2007216226B2/en active Active
- 2007-02-13 BR BRPI0706992A patent/BRPI0706992C8/pt active IP Right Grant
- 2007-02-13 NZ NZ569797A patent/NZ569797A/en unknown
- 2007-02-13 PT PT77338846T patent/PT1991541E/pt unknown
- 2007-02-13 EA EA200801580A patent/EA015605B1/ru unknown
- 2007-02-26 TW TW096106545A patent/TWI501960B/zh active
-
2008
- 2008-08-04 IL IL193236A patent/IL193236A/en active IP Right Grant
- 2008-08-06 ZA ZA200806799A patent/ZA200806799B/xx unknown
- 2008-09-12 NO NO20083905A patent/NO339826B1/no unknown
-
2009
- 2009-06-21 HK HK09105568.2A patent/HK1126760A1/xx unknown
- 2009-11-04 US US12/612,001 patent/US8242163B2/en active Active
-
2012
- 2012-07-13 US US13/549,181 patent/US8569355B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0706992C8 (pt) | composto de fórmula (i) e formulação farmacêutica | |
BRPI0607796A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica | |
BRPI0610850A2 (pt) | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados | |
SV2011003786A (es) | Compuestos quimicos 251 | |
BRPI0814299B8 (pt) | preparação sólida compreendendo alogliptina e cloridreto de metformina, uso de uma preparação sólida, e, métodos para estabilizar um composto em uma preparação sólida, e para produzir uma preparação sólida | |
BR122017015098B8 (pt) | formulações farmacêuticas de liberação imediata que contêm hidrato de propileno glicol de dapagliflozina | |
GT200800256A (es) | Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios | |
GT200500137A (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis. | |
BRPI0916735B8 (pt) | compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos | |
BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
BRPI0508540A8 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
CR11857A (es) | Compuestos pirazolicos 436 | |
BRPI0714803B8 (pt) | compostos peptidomiméticos de smac, seus usos, e composição farmacêutica | |
BRPI0906444A8 (pt) | compostos de 4-piridinona e seu uso para câncer | |
BRPI0507966A (pt) | uso de meloxicam para o tratamento de doenças respiratórias em porcos | |
BRPI0517701A (pt) | uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus | |
BRPI0821855B8 (pt) | composto, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
BR112014018953A8 (pt) | Derivados de lupano triterpenoide e uso farmacêutico dos mesmos | |
BRPI0806789B8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
BR112014017985A8 (pt) | Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer | |
BRPI0513857A (pt) | inibidores de hsp90 | |
BRPI0519351A2 (pt) | medicamentos para o tratamento ou prevenÇço de doenÇas fibràticas | |
BRPI0913291A2 (pt) | composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto | |
BRPI0916282B8 (pt) | uso de um agonista do receptor-pgi2 no tratamento de insuficiência renal crônica | |
BR112012013252A2 (pt) | composição farmacêutica tópica, preservativo, composto, e, uso do mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/02/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2626 DE 04/05/2021 QUANTO AO ENDERECO. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/02/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |